Morgan Stanley, Cantor Fitzgerald, and BTIG raise Viking Therapeutics (VKTX) price targets to $102-$125, citing accelerated obesity trials and upcoming FDA meeting for oral treatment.
President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's leadership in cardiometabolic disease.
Pfizer is buying Metsera for $4.9 billion to gain promising new obesity drugs. The portfolio includes four clinical treatments, like once-a-month shots and future oral pills, aiming for better efficacy and easier patient use to fight the growing obesity epidemic.
Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.
The "Wegovy in a pill" (oral semaglutide 25 mg) shows huge promise for weight loss! Patients lost an average of 16.6% body weight, comparable to the injection. It's the first oral GLP-1 for weight management, offering convenience, and awaits FDA approval.
